Investment Summary

Stonebridge Capital Invests In SK Incheon Petrochem

On December 31, 2013, private equity firm Stonebridge Capital invested in chemicals company SK Incheon Petrochem

Investment Highlights
  • This is Stonebridge Capital’s 1st transaction in the Chemicals sector.
  • This is Stonebridge Capital’s 7th transaction in South Korea.

Investment Summary

Date 2013-12-31
Target SK Incheon Petrochem
Sector Chemicals
Investor(s) Stonebridge Capital
Deal Type Growth Capital

Target

SK Incheon Petrochem

Incheon, South Korea
website
SK Incheon Petrochem Co.,Ltd. provides oil and gas services.

Search 177,829 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Stonebridge Capital

Seoul, South Korea

Investor Investor Investor Investor

website


Category Private Equity Firm
Founded 2008
PE ASSETS 118M KRW
Size Small
Type Sector Agnostic
DESCRIPTION

Stonebridge Capital is a Korean private equity and venture capital firm focused on investing in growth businesses at all company stages. Stonebridge looks for businesses that have the potential to be market leaders. Sectors of interest include consumer goods, value-added manufacturing, media/entertainment, healthcare, financial services, business services, real estate, and oil/gas exploration. The Firm generally targets businesses operating in Korea, China, and Japan. Stonebridge Capital was formed in 2008 and is based in Seoul.


DEAL STATS #
Overall 7 of 8
Sector (Chemicals) 1 of 1
Type (Growth Capital) 7 of 7
Country (South Korea) 7 of 7
Year (2013) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-01-01 Corentec

Cheonan, South Korea

Corentec is a medical device technology company that manufacturers artificial joints. Corentec was founded in 2000 and is based in Cheonan, South Korea.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-01-01 Green Cross Biotherapeutics

Montreal, Quebec, Canada

Green Cross Biotherapeutics, Inc. specializes in the development and manufacture of plasma derivatives, preventive vaccines, recombinant proteins and therapeutic antibodies.

Buy -